Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are widely used in diabetes mellitus (DM) and cardiovascular disease for their glycemic and cardioprotective benefits. This evidence concerns the gene SLC5A2 and cardiovascular disorder.